Alterity Therapeutics Appoints Biotech Veteran Ann Cunningham to Board

Cunningham brings over 25 years of global pharmaceutical and biotech experience to support Alterity's late-stage development of ATH434 for Multiple System Atrophy.

Apr. 17, 2026 at 11:51am by

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life featuring a collection of polished, geometric objects in shades of silver, grey, and black, conceptually representing the pharmaceutical industry and neurodegenerative disease research.Alterity Therapeutics appoints biotech veteran Ann Cunningham to its Board, strengthening the company's leadership and commercial expertise as it advances its lead Parkinson's drug candidate.San Francisco Today

Alterity Therapeutics, a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, announced the appointment of Ann Cunningham to its Board of Directors as an independent Non-Executive Director. Cunningham's extensive commercial and strategic expertise in the pharmaceutical industry, particularly in neurodegenerative diseases and psychiatry, will be valuable as Alterity prepares to advance its lead candidate ATH434 into Phase 3 clinical trials for Multiple System Atrophy (MSA).

Why it matters

Cunningham's appointment strengthens Alterity's Board as the company transitions its lead asset ATH434 toward late-stage development for MSA, a rare and rapidly progressive neurodegenerative disorder with significant unmet medical need. Her experience in shaping commercial strategy and leading successful product launches will be crucial in positioning ATH434 for potential commercialization.

The details

Cunningham brings over 25 years of global pharmaceutical and biotechnology experience, having held senior roles at companies like Eli Lilly and Teva Pharmaceuticals. She has deep expertise in commercial strategy and leadership across neurodegenerative diseases and psychiatry, and has been instrumental in the successful launches of products like Lilly's Cymbalta and Otsuka's Rexulti.

  • Cunningham's appointment to Alterity's Board is effective as of April 17, 2026.

The players

Ann Cunningham

Founder and Chief Executive Officer of i³ Strategy Partners, a pharmaceutical consulting group focused on improving health outcomes through innovative patient engagement strategies.

Alterity Therapeutics

A clinical-stage biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases, with a focus on Multiple System Atrophy (MSA).

Julian Babarczy

Non-Executive Chairman of the Board of Directors at Alterity Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We are delighted to welcome Ann to the Alterity Board at a pivotal stage in the Company's evolution as we prepare to advance ATH434 into Phase 3 development.”

— Julian Babarczy, Non-Executive Chairman of the Board of Directors

“I am excited to join Alterity at such a pivotal time, with promising clinical data driving strong momentum for ATH434 as a potential disease modifying treatment for patients suffering from neurodegenerative diseases.”

— Ann Cunningham

What’s next

Alterity is preparing to initiate a Phase 3 pivotal trial for ATH434 in MSA, a rare and rapidly progressive disease.

The takeaway

Alterity's appointment of biotech veteran Ann Cunningham to its Board of Directors strengthens the company's leadership and commercial expertise as it advances its lead candidate ATH434 toward late-stage development for the treatment of Multiple System Atrophy, a significant unmet medical need.